UNASSIGNED: The subjects were 210 MM patients who underwent stem cell mobilization procedure between 2018 and 2022. Solo granulocyte colony-stimulating factor (G-CSF) was administered in 104 cases, while 106 patients received chemotherapy which was followed by G-CSF administration. We evaluated the ratio of successful mobilizations, the amount of collected stem cells, the incidence of infections and cost-effectivity in the two groups.
UNASSIGNED: In the steady-state group, there was a significantly higher need for plerixafor (45% vs. 13%, P < 0.001), unsuccessful stem cell mobilization was more frequent (11% vs. 3%, P = 0.024) and the mean amount of collected stem cells was lower (6.9 vs. 9.8 × 106, P < 0.001) than in the chemotherapy group. However, infections were less frequent (4% vs. 27%, P < 0.001) and the number of days spent in hospital was significantly lower (6 vs. 14 days, P < 0.001). Plerixafor was more frequently administered in those who had received lenalidomide or daratumumab than in those who had been treated with other regimens (41% vs. 23%, P = 0.007 and 78% vs. 23%, P < 0.001, respectively).
UNASSIGNED: Steady-state mobilization is a safe method; however, the higher rate of plerixafor administration and unsuccessful attempts may question its superiority to chemomobilization.
■受试者是210名MM患者,他们在2018年至2022年之间接受了干细胞动员程序。应用粒细胞集落刺激因子(G-CSF)104例,而106例患者接受化疗,随后给予G-CSF。我们评估了成功动员的比例,收集的干细胞的数量,两组的感染发生率和成本效益。
■在稳态组中,对plerixafor的需求显著增加(45%与13%,P<0.001),不成功的干细胞动员更频繁(11%vs.3%,P=0.024),收集的干细胞的平均数量较低(6.9vs.9.8×106,P<0.001)高于化疗组。然而,感染频率较低(4%vs.27%,P<0.001),住院天数显着降低(6vs.14天,P<0.001)。与接受其他方案治疗的患者相比,接受来那度胺或达拉图单抗的患者更频繁地使用Plerixafor(41%vs.23%,P=0.007和78%vs.23%,分别为P<0.001)。
■稳态动员是一种安全的方法;然而,plerixafor给药的比率较高,尝试失败,可能会质疑其对化学移植的优越性。